文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

兔抗胸腺细胞球蛋白两种剂量治疗重型再生障碍性贫血的前瞻性随机对照研究

Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia.
PubMed 文献 · Br J Haematol · 2019-06-17

该研究为前瞻性、随机、多中心试验,纳入日本、中国、韩国共222例重型再生障碍性贫血(SAA)患者,1:1随机接受兔抗胸腺细胞球蛋白(rATG)2.5 mg/kg或3.5 mg/kg,均连用5天。主要终点第180天血液学缓解率在两组间无显著差异(49% vs 48%,P=0.894),3年总生存率亦无显著差异。

要点

  • 第180天缓解率:2.5 mg/kg组49% vs 3.5 mg/kg组48%,P=0.894,无显著差异。
  • 3年总生存率:2.5 mg/kg组85%(95%CI 76%-91%)vs 3.5 mg/kg组91%(95%CI 82%-96%),P=0.107。
  • 研究显示两种剂量rATG在SAA患者中的疗效与安全性均无显著差异。

核心结论

  • 本研究显示,rATG 2.5 mg/kg与3.5 mg/kg剂量在SAA患者中的疗效和安全性均无显著差异。

研究设计与样本

  • 前瞻性、随机、多中心研究,比较两种剂量rATG在SAA患者中的效果。
  • 2012年5月至2017年10月期间,在日本(n=89)、中国(n=85)和韩国(n=48)入组需初始免疫抑制治疗的SAA患者。
  • 共222例患者按1:1区组随机化,112例接受rATG 2.5 mg/kg,110例接受3.5 mg/kg,均连用5天。
  • 主要终点为第180天血液学缓解率。

主要发现

  • 第6个月时,2.5 mg/kg组与3.5 mg/kg组的缓解率分别为49%与48%,差异无统计学意义(P=0.894)。
  • 3年总生存率在2.5 mg/kg组为85%(95%CI 76%-91%),在3.5 mg/kg组为91%(95%CI 82%-96%),差异无统计学意义(P=0.107)。

关键数值与推荐

  • rATG 2.5 mg/kg连用5天:第180天缓解率49%,3年总生存率85%(95%CI 76%-91%)。
  • rATG 3.5 mg/kg连用5天:第180天缓解率48%,3年总生存率91%(95%CI 82%-96%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of choice for patients with severe aplastic anaemia (SAA) includes immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and ciclosporin A. However, the optimal dose for rabbit ATG has yet to be established. We herein report the first prospective, randomized, multicentre study comparing two doses of rabbit ATG in patients with SAA. Patients with SAA who required initial IST in Japan (n = 89), China (n = 85) and Korea (n = 48) were enrolled between May 2012 and October 2017. A 1:1 block randomization was employed for two doses of rabbit ATG. In total, 222 patients were randomized, with 112 patients receiving 2·5 mg/kg and 110 receiving 3·5 mg/kg of rabbit ATG for 5 days. The primary endpoint was the haematological response at day 180. After 6 months, no significant difference in response rates was observed between the 2·5 and 3·5 mg/kg groups (49% vs. 48%, P = 0·894). Overall survival at 3 years was similar between the two groups [85% (95% confidence interval [CI], 76%-91%) vs. 91% (95% CI, 82%-96%); P = 0·107]. The current study revealed no significant differences in the efficacy and safety between the 2·5 and 3·5 mg/kg doses of rabbit ATG in patients with SAA. Trial registration: UMIN000011134.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Narita A, Zhu X, Muramatsu H, et al. Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia. Br J Haematol. 2019. PMID: 31206607. doi:10.1111/bjh.16055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。